Request Demo
Last update 29 Aug 2025
Dexrazoxane Hydrochloride
Last update 29 Aug 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms dexrazoxane, Topotect, Totect + [13] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 May 1995), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Australia) |
Login to view timeline
Structure/Sequence
Molecular FormulaC11H17ClN4O4 |
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N |
CAS Registry149003-01-0 |
Related
55
Clinical Trials associated with Dexrazoxane HydrochlorideChiCTR2500101472
Early Application of Edaravone Dexrazoxane In The Treatment of Acute Non-Large Vessel Occlusive Ischemic Stroke
NCT06647953
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
NCT06220032
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
100 Clinical Results associated with Dexrazoxane Hydrochloride
Login to view more data
100 Translational Medicine associated with Dexrazoxane Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dexrazoxane Hydrochloride
Login to view more data
1,077
Literatures (Medical) associated with Dexrazoxane Hydrochloride01 Dec 2025Natural Products and Bioprospecting
Design, synthesis and biological evaluation of buthutin derivatives as cardioprotective agents
Article
Author: Liu, Yu-Ming ; Wang, Li-Ning ; Gou, Xiang-Bo ; Yang, Shu-Han ; Hua, Xin-Hao ; Wang, Fa-Qi ; Xu, Yun-Sheng ; Liu, Yuan ; Shao, Chen-Yue
Abstract:
Natural products are the important sources in cardiovascular drug development. In this study, twenty-nine buthutin derivatives were designed, synthesized, and evaluated for their NHE-1 inhibition and protective effects on cardiomyocyte injury. The structure of the newly synthesized compounds had been confirmed by 1H-NMR, 13C-NMR, and HR-ESI-MS spectra. Among all target compounds at 1 μM, compounds 9d, 9f, 9k, 9m, and 9n, with a protection ratio exceeding 30%, exerted stronger protective effects on H9c2 cardiomyocyte than positive control dexrazoxane and buthutin A. Meanwhile, compounds 9k, 9m, and 9o showed the significant NHE-1 inhibitory activities on H9c2 cardiomyocyte, all with a dpHi/min value less than 0.23. What is more, compounds 9k, 9m, 9o and buthutin A all exhibited the specificity on NHE-1 inhibition. Molecular modelling studies suggested the ability of compounds 9m and 9o to establish interactions with three hydrogen bonds to Asp267 and Glu346 of NHE-1, but also the ability with much lower CDOCKER energies than positive control cariporide and buthutin A. The structure–activity relationship (SAR) studies suggested that the presences of amide group, four-carbon linker, and para hydroxyl benzene ring were advantageous pharmacophores for above two pharmacological actions. This research would open new avenues for developing amide-guanidine-based cardioprotective agents.Graphical Abstract
01 Oct 2025BIOCHEMICAL PHARMACOLOGY
Herbacetin mitigates oxidative stress and ferroptosis to protect against doxorubicin-induced cardiotoxicity
Article
Author: Xin, Wenxu ; Sun, Ning ; Yang, Hai ; Huang, Shaohong ; Zhang, Ke ; Ye, Chao ; Heng, Xinyu
The chemotherapy agent doxorubicin (DOX) is significantly constrained in its clinical application due to its notable cardiotoxicity. Dexrazoxane is the only drug approved by the FDA for the prevention of DOX-induced carditoxicity; however, it may also diminish the sensitivity of cancer cells to DOX chemotherapy. Consequently, there is an urgent need for the development of safe and effective therapeutic agents to mitigate the cardiotoxic effects induced by DOX. In this study, C57BL/6J mice and H9C2 cardiomyocytes were employed to establish models of DOX-induced cardiotoxicity. We examined the effects of herbacetin on myocardial damage, cardiac function, oxidative stress, ferroptosis and the associated signaling pathways using a variety of experimental techniques. Our results demonstrated that herbacetin mitigated DOX-induced myocardial damage and cardiac dysfunction both in vivo and in vitro. Mechanistically, herbacetin inhibits oxidative stress and lipid peroxidation by directly binding to tyrosine 342 of acyl-CoA synthetase long-chain family member 4 (ACSL4). This interaction inhibits lipid peroxidation and ferroptosis, suggesting that herbacetin may serve as a promising ferroptosis inhibitor and therapeutic agent for diseases associated with ferroptosis. This study underscores the therapeutic potential of herbacetin in DOX-induced cardiotoxicity and highlights the importance of modulating ACSL4 activity and inhibiting lipid peroxidation in diseases associated with ferroptosis.
01 Sep 2025British Journal of Pharmacology
Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study
Article
Author: Lapré, Thirza A. ; van der Kraak, Petra ; van der Harst, Pim ; Sluijter, Joost P. G. ; Mokhles, M. Mostafa ; Kelters, Ilse R. ; van Laake, Linda W. ; de Boer, Teun P. ; van Ham, Willem B. ; Benavente, Ernest Diez ; Teske, Arco J. ; Sampaio‐Pinto, Vasco ; Arends, Bauke ; van der Geest, Jort S. A. ; Dendorfer, Andreas ; Doevendans, Pieter A.
Abstract:
Background and Purpose:
The increasing number of cancer survivors has caused growing concern over chemotherapy‐induced cardiotoxicity. This study aimed to investigate a novel human model of cardiotoxicity and explore cardioprotection.
Experimental Approach:
Living myocardial slices (LMS) were obtained from explanted end‐stage heart failure hearts, then exposed to doxorubicin (Dox) to investigate cardiotoxic effects and to dexrazoxane (Dex) to explore cardioprotection. We assessed contractile function and glucose consumption, followed by evaluation of calcium transients, structural integrity and transcriptomic changes. Additionally, electrocardiogram (ECG) alterations were analysed in patients treated with anthracyclines to corroborate the cardiotoxicity findings from LMS.
Key Results:
We observed distinct functional responses to Dox, with LMS derived from some patients exhibiting high susceptibility to Dox‐induced cardiotoxicity. LMS from susceptible patients displayed reduced contractile function and excitability, myofibre dyssynchrony, structural damage and decreased metabolic activity. Dex pretreatment partially mitigated these effects, preserving contractile function and preventing structural damage. Consistent with ex vivo findings, patients treated with anthracyclines exhibited acute and chronic alterations in T‐, P‐ and R‐wave morphology of the ECG, confirming variable susceptibility at the clinical level.
Conclusions and Implications:
We highlight the value of human LMS in studying Dox‐induced cardiotoxicity and the cardioprotective potential of Dex, even when sourced from end‐stage heart failure patients. Susceptible patients harboured cardiomyopathy‐associated genetic mutations, suggesting that genetic screening including cardiomyopathy‐associated genes, prior to anthracycline treatment, could enable improved patient risk stratification. We demonstrate the potential utility of ECG changes for early detection of subclinical cardiotoxicity.
5
News (Medical) associated with Dexrazoxane Hydrochloride11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
100 Deals associated with Dexrazoxane Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07807 | Dexrazoxane Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extravasation of Diagnostic and Therapeutic Materials | European Union | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Iceland | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Liechtenstein | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Norway | 27 Jul 2006 | |
| Cytoprotective Agent | China | 29 May 2006 | |
| Cardiomyopathies | United States | 26 May 1995 | |
| Metastatic breast cancer | United States | 26 May 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Phase 3 | Denmark | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Germany | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Italy | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Netherlands | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Poland | 01 Apr 2002 | |
| Bronchitis | Phase 3 | Denmark | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 25 | (Dexrazoxane 100mg/m2) | jaloncfxtr = gyepfwaqbx ghxyqxeiyc (bceczdvyxj, evsryutnhm - ejucwfrudc) View more | - | 12 Jun 2025 | ||
(Dexrazoxane 200mg/m2) | jaloncfxtr = pluaxrjjbr ghxyqxeiyc (bceczdvyxj, sfekxqeazz - jnzeslqxxw) View more | ||||||
Not Applicable | 263 | uymjstlicm(ubakhhzjex) = hxmsfyrfek vubjcsgqsp (hzogtcefsq ) View more | - | 03 Dec 2022 | |||
uymjstlicm(ubakhhzjex) = tucsvgraap vubjcsgqsp (hzogtcefsq ) View more | |||||||
Not Applicable | - | 1,308 | ttzfdrffcj(xocjwfjcwb): HR = 1.07 (95% CI, 0.78 - 1.47) View more | - | 15 Feb 2022 | ||
Phase 2 | 46 | (Arm A: VACdxr With ImmTher) | wwnttxbabd(agrluqlzlr) = lwdsevhcqt uoqmjidxsi (vwtpiqvxbw, kvgvskjmvu - wuouirqces) View more | - | 29 Jan 2020 | ||
(Arm B: VACdxr) | wwnttxbabd(agrluqlzlr) = kkzkvublia uoqmjidxsi (vwtpiqvxbw, tasegobjcm - jnmzkfvseu) View more | ||||||
Phase 1 | 1 | uqjmykcoht = zshvhtkbmq jnxlswaiyk (qcxctqfesy, arrbjcxsfa - ymibldfpkk) View more | - | 19 Feb 2019 | |||
Not Applicable | 1,014 | hoiekzynnx(snvcxtxhde) = deicdjptmq xqdapoijzk (bqxemmapcd ) View more | Positive | 01 Jun 2018 | |||
hoiekzynnx(snvcxtxhde) = xtrvgtofsy xqdapoijzk (bqxemmapcd ) View more | |||||||
Phase 1/2 | 2 | zsmkeqviau = mlouvlmlea dzdjzadhrq (slwfcozzqq, ijmteucyvv - qwimratxck) View more | - | 13 Mar 2015 | |||
Not Applicable | 7 | (Outpatient Chemotherapy) | remipirhrf(yezkazgnor) = tlfkbplmot ehsplembxl (pcxorrqmmf, nmvyowunyq - bygzexdidb) View more | - | 10 Sep 2014 | ||
Surgery+Dexrazoxane+Mesna+Leucovorin+Doxorubicin+ifosfamide+Gemcitabine+Sargramostim+Methotrexate+cisplatin (Additional Risk-Adapted Outpatient Chemotherapy) | remipirhrf(yezkazgnor) = sihkixmsac ehsplembxl (pcxorrqmmf, vrqxnwgpah - zpqviakpnc) View more | ||||||
Phase 2 | 7 | neoadjuvant therapy+dexrazoxane hydrochloride+filgrastim+doxorubicin hydrochloride+ifosfamide+irinotecan hydrochloride | yghgizzfpo = zppopkroof hzmucucczq (mdvhcjproj, wrincigpwq - qykhkzwivz) View more | - | 28 Aug 2014 | ||
Phase 1 | 24 | therapeutic conventional surgery+dexrazoxane hydrochloride+Mesna+etoposide+Leucovorin Calcium+zoledronic acid+filgrastim+doxorubicin hydrochloride+ifosfamide+Cisplatin+methotrexate (Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid) | sbexcmkpye = msvvecvsxx ggrvxkfjqg (tcvruoecrj, aigblcvknt - lfzryslwpv) View more | - | 04 Jul 2014 | ||
therapeutic conventional surgery+dexrazoxane hydrochloride+Mesna+etoposide+Leucovorin Calcium+zoledronic acid+filgrastim+doxorubicin hydrochloride+ifosfamide+Cisplatin+methotrexate (Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid) | sbexcmkpye = mlvfwaobdn ggrvxkfjqg (tcvruoecrj, jppwhqlquk - fhikrtidtx) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free